Yang Yang, Ting Wang, Xiao Liu, Shufei Fu, Wangxiao Tan, Xiaoying Wang, Xiumei Gao, Boli Zhang
State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.
State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China; College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.
Evid Based Complement Alternat Med. 2017;2017:5121538. doi: 10.1155/2017/5121538. Epub 2017 Jan 5.
. Immunosuppression is a well-recognised complication of chemotherapy in cancer patients. We assemble the clinical evidence that SQI, an adjuvant drug for lung cancer and gastric cancer which was widely prescribed in China, interventions could increase objective tumour response and regulate immunity in cancer patients undergoing chemotherapy. We undertook a systemic review of the clinical data from randomised controlled trials up to September 2015 in which a SQI intervention was compared with a control arm in patients undergoing conventional chemotherapy. Revman 5.0 Software was used for the data analysis. 49 randomised controlled trials were included in the systematic review. The meta-analysis results demonstrated that the SQI intervention with conventional chemotherapy exhibited better therapeutic efficacy than the conventional chemotherapy group with a statistically significant higher objective tumour response. Cotreatment with SQI could enhance NK, CD, CD level, and CD/CD ratio comparing with the conventional chemotherapy group. The conclusions of this review might suggest a high risk of bias due to the low quality and the limitation of cancer types in the included trials. A more reliable conclusion regarding the immunoregulation of SQI could be reached based on more trials of higher quality.
免疫抑制是癌症患者化疗中一种公认的并发症。我们收集了临床证据，表明参芪扶正注射液（SQI）作为中国广泛使用的肺癌和胃癌辅助药物，其干预措施可提高癌症化疗患者的客观肿瘤反应并调节免疫力。我们对截至2015年9月的随机对照试验临床数据进行了系统评价，其中将接受参芪扶正注射液干预的患者与接受传统化疗的对照组进行了比较。使用Revman 5.0软件进行数据分析。系统评价纳入了49项随机对照试验。荟萃分析结果表明，参芪扶正注射液联合传统化疗的疗效优于单纯传统化疗组，客观肿瘤反应在统计学上显著更高。与传统化疗组相比，参芪扶正注射液联合治疗可提高自然杀伤细胞（NK）、CD、CD水平以及CD/CD比值。本综述的结论可能表明，由于纳入试验的质量较低和癌症类型的局限性，存在较高的偏倚风险。基于更多高质量的试验，可以得出关于参芪扶正注射液免疫调节作用的更可靠结论。
